Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Point Therapeutics commences last planned phase II studies for talabostat

July 5, 2004

CF-101 enters phase I study in solid tumor patients

July 5, 2004

PXD-101 enters phase I trial in hematologic cancer

July 2, 2004

Erbitux receives E.U. approval for metastatic colorectal cancer

July 2, 2004

Femara sNDA granted priority review by FDA

July 2, 2004

New IGF-1R inhibitors with potential in cancer therapy

July 2, 2004

Novel topoisomerase inhibitors identified by researchers at State U. of New Jersey

July 2, 2004

Retinoic metabolism inhibitors promising against prostate cancer

July 2, 2004

Exelixis submits IND for XL-999

July 2, 2004

FDA accepts IND for MN-029

July 2, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Sun Pharma to acquire Merck spinoff Organon for $11.75B
BioWorld
Sun Pharmaceuticals Industries Ltd. will pay $11.75 billion cash to acquire Organon & Co. The transaction is expected to close in early 2027. The addition of...